Results 101 to 110 of about 68,138 (263)

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes, Rishi S. Kotecha, Derek J. Roebuck   +2 more
wiley   +1 more source

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, EarlyView.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real‐world study in Quebec

British Journal of Haematology, EarlyView.
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent‐Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté   +10 more
wiley   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Chronic Splenomegaly [PDF]

Proceedings of the Royal Society of Medicine, 1937
G, Slot, G S, Caithness
openaire   +2 more sources

Cystic Splenomegaly [PDF]

Journal of Travel Medicine, 2011
Vanina, Meyssonnier, Tamara, Makovec, Eric, Caumes   +2 more
openaire   +2 more sources

GLUT1 Deficiency Syndrome with Coexistent Movement Disorder and Anemia

Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan, Haya S AlFaris, Anika Menetrey, Sayoni Roy Chowdhury, Lindsey Vogt, Jolynn Dickson, Karen Owusu, Pradeep Krishnan, Suvasini Sharma, Liali Aljouda, Reena Pabari, Grace Yoon, Carolina Gorodetsky   +12 more
wiley   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care

British Journal of Haematology, EarlyView.
Girard et al. report a retrospective, single‐centre, real‐world study evaluating hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease in Quebec. Hydroxyurea was associated with reduced vaso‐occlusive crisis composite events, mostly mild adverse events and no observed hyperviscosity‐related complications, while highlighting adherence
Tahereh Setayesh
wiley   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source